InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,174.00
(
1.14%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.67
(
0.57%
)
Bitcoin
61,592.68
(
-0.35%
)
Post# of 252358
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119916
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Fred Kadiddlehopper post# 184994

Monday, 12/22/2014 10:25:18 AM

Monday, December 22, 2014 10:25:18 AM

Post# of 252358

One can be sure that JnJ's legal department will be working overtime starting today.

Actually, I doubt that. JNJ is no longer a serious player in the HCV market because they’ve developed only a single drug (simeprevir) rather than a full HCV regimen. Thus, ESRX could successfully argue that JNJ wasn’t going to be able to maintain any meaningful market share regardless of ESRX’s actions.

At this point, the “collusion” issue (as posited by ‘bladerunner’) affects only ABBV and GILD.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up